You just read:

Updated Analysis of Phase III ALSYMPCA Study for Bayer's Investigational Compound Radium-223 Dichloride to be Presented at the 48th Annual ASCO Meeting

News provided by

Bayer HealthCare

04 Jun, 2012, 00:09 ET